Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial

Phase 3 Active not recruiting 100 enrolled The Hospital for Sick Children Canadian Institutes of Health Research (CIHR) · collab Juvenile Diabetes Research Foundation · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The ATTEMPT (Adolescent Type 1 diabetes Treatment with SGLT2i for hyperglycEMia \& hyPerfilTration Trial) is a multi-center, double-blinded, randomized, placebo-controlled trial to evaluate the effect of treatment with Dapagliflozin when compared to placebo, in combination with adjustable insulin, on measured GFR in adolescents with T1D 12 to \<19 years of age over a 16-week treatment period.

Timeline

Start: 2020-12-11
Primary completion: 2024-05
Completion: 2024-05

Outcome

Met primary endpoint

paper Dapagliflozin reduced mGFR by 8.8 ml min-1 1.73 m-2 when compared to placebo (95% confidence interval (CI): -12.7 to -4.8; P < 0.0001) PMID 40481206 ↗

Publications

Mahmud FH, Bjornstad P, Clarson C, Clarke A, Anthony SJ, Curtis J, Elia YT, McArthur L, Mertens L, Moineddin R, Kirsch S, Coles N, Maione M, Furman M, Babalola F, Tommerdahl KL, Harrington J, Riddell MC, Prasad P, Huang L, Heerspink HJL, Cherney DZI. Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial. Nat Med. 2025 Jul;31(7):2317-2324. doi: 10.1038/s41591-025-03723-6. Epub 2025 Jun 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dapagliflozin	Small molecule	5 mg	Oral